Enhancing the Target and Biomarker Discovery Efforts of the AMP-AD and M2OVE-AD Consortia (R01)

Funding Agency:
National Institutes of Health

This funding opportunity invites applications that would enhance the goals and deliverables of the AMP-AD Target Discovery and Preclinical Validation and M2OVE Consortia by maximizing the usability of the data and analytical results generated by these programs, seizing opportunities for additional target and biomarker discovery, and accelerating the validation of the novel targets and biomarkers being discovered within the AMP-AD and M2OVE-AD Consortia.

Application Due Date(s): February 3, 2017

RFA-AG-17-054 Expiration Date February 4, 2017

Agency Website



Amount Description

Annual direct costs are capped at $750,000.

The total project period for an application submitted in response to this FOA may not exceed 3 years. 

Funding Type





Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 3, 2017